C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States

Summary

The purpose of the CASCADE-3002 project is to improve access to cervical cancer screening among women with Human Immunodeficiency Virus (HIV) receiving care at U.S.-based CASCADE clinical sites. This study will assess the cervical cancer screening cascade and identify multilevel factors that impede access to screening among women with HIV attending Infectious Disease clinics in Georgia and Maryland. In parallel, the study will explore and develop implementation strategies for human papillomavirus (HPV) self-collection to increase screening uptake, adherence, and appropriate clinical follow-up in this population at elevated risk for cervical cancer.

Cervical cancer remains a preventable malignancy; however, women with HIV are at substantially increased risk and experience higher rates of cervical cancer compared with women without HIV. The World Health Organization has called for the global elimination of cervical cancer as a public health problem, defined as fewer than 4 incident cases per 100,000 women annually, with targets for vaccination, screening, and treatment coverage. Although the United States has the tools to approach near-elimination, disparities in healthcare access and screening persist, particularly among women with HIV.

Conditions

• Human Immunodeficiency Virus (HIV)
• Human Papillomavirus (HPV)
• Cervical Cancer
• Cervical Precancer

Interventions

BEHAVIORAL

Qualitative interviews

In-depth qualitative interviews will be conducted with women with Human Immunodeficiency Virus (HIV) receiving care to explore barriers and facilitators to cervical cancer screening and follow-up care.

BEHAVIORAL

Focus groups

Focus groups will be conducted with multidisciplinary care team members to assess perceived clinical workflow challenges, access barriers, and health system constraints related to current cervical cancer screening and follow-up protocols.

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• UNC Lineberger Comprehensive Cancer Center

  lead OTHER

Principal Investigators

• Jennifer S Smith, PhD · University of North Carolina, Chapel Hill

• Lisa Rahangdale, MD, MPH · University of North Carolina, Chapel Hill

• Clement S Adebamowo, ScD · University of Maryland SOM

• Gregory Taylor, MD · University of Maryland SOM

• Lisa Flowers, MD, MPH · Emory University

• Anandi Sheth, MD, MSc · Emory University

• Michael Hudgens, PhD · University of North Carolina, Chapel Hill

• Katie Mollan, PhD · University of North Carolina, Chapel Hill

• Vikrant Sahasrabuddhe, MBBS, MPH, DrPH · Division of Cancer Prevention (DCP), NCI

• Laura Gaydos, PhD · Emory University

• Patrick Ryscavage, MD · University of Maryland SOM

• Sue Siminski · Frontier Science Foundation

• Kayla Denson · Frontier Science Foundation

• Nicole Freitag · Frontier Science Foundation

Eligibility

Min Age

25 Years

Max Age

49 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2026-04-30

Primary Completion

2027-02-28

Completion

2027-05-31

Countries

• United States

Study Locations